|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:34-42
© 2006 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, United Kingdom.
Received for publication March 14, 2005; revisions received May 11, 2005; accepted for publication May 26, 2005. * Address for reprints: Robert S. Bonser, FRCP, FRCS, Consultant Cardiothoracic Surgeon, Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, University Hospital Birmingham NHS trust, Edgbaston, Birmingham, UK, B15 2TH. (Email: robert.bonser{at}uhb.nhs.uk).
OBJECTIVE: We sought to assess the role of glucose-insulin-potassium in providing myocardial protection in nondiabetic patients undergoing coronary artery surgery with cardiopulmonary bypass.
METHODS: A prospective, randomized, double-blind, placebo-controlled trial was conducted at a single-center university hospital performing adult cardiac surgery. Two hundred eighty nondiabetic adult patients undergoing first-time elective or urgent isolated multivessel coronary artery bypass grafting were prospectively randomized to receive glucose-insulin-potassium infusion or placebo (dextrose 5%) before, during, and for 6 hours after surgical intervention. Anesthetic, cardiopulmonary bypass, myocardial protection, and surgical techniques were standardized. The primary end point was postreperfusion cardiac index. Secondary end points were systemic vascular resistance index, the incidence of low cardiac output episodes, inotrope and vasoconstrictor use, and biochemical-electrocardiographic evidence of myocardial injury. The incidence of dysrhythmias and infections requiring treatment was recorded prospectively.
RESULTS: The glucose-insulin-potassium group experienced higher cardiac indices (P < .001) throughout infusion and reduced vascular resistance (P < .001). The incidence of low cardiac output episodes was 15.9% (22/138) in the glucose-insulin-potassium group and 27.5% (39/142) in the placebo group (P = .021). Inotropes were required in 18.8% (26/138) of the glucose-insulin-potassium group and 40.8% (58/142) of the placebo group (P < .001). Fewer patients in the glucose-insulin-potassium group (12.3% [16/133]) versus those in the placebo group (23.4% [32/137]) had significant myocardial injury (P = .017). Noncardiac morbidity was not different.
CONCLUSION: Glucose-insulin-potassium therapy improves early postoperative cardiovascular performance, reduces inotrope requirement, and might reduce myocardial injury. These potential benefits are not at the expense of increased noncardiac morbidity.
Related Article
J. Thorac. Cardiovasc. Surg. 2006 131: 11-13.
This article has been cited by other articles:
![]() |
M. A. Puskarich, M. S. Runyon, S. Trzeciak, J. A. Kline, and A. E. Jones Effect of Glucose-Insulin-Potassium Infusion on Mortality in Critical Care Settings: A Systematic Review and Meta-Analysis J. Clin. Pharmacol., July 1, 2009; 49(7): 758 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, V. E. Laubach, B. A. French, and I. L. Kron Acute hyperglycemia enhances oxidative stress and exacerbates myocardial infarction by activating nicotinamide adenine dinucleotide phosphate oxidase during reperfusion. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 723 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ceriello, S. W. Zarich, and R. Testa Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S9 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dandona, A. Chaudhuri, H. Ghanim, and P. Mohanty Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S14 - S20. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Zuurbier, F. J. Hoek, J. van Dijk, N. G. Abeling, J. C. M. Meijers, J. H. M. Levels, E. de Jonge, B. A. de Mol, and H. B. Van Wezel Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery Br. J. Anaesth., April 1, 2008; 100(4): 442 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y. Gandhi, M. H. Murad, D. N. Flynn, P. J. Erwin, A. B. Cavalcante, H. B. Nielsen, S. E. Capes, K. Thorlund, V. M. Montori, and P. J. Devereaux Effect of Perioperative Insulin Infusion on Surgical Morbidity and Mortality: Systematic Review and Meta-analysis of Randomized Trials Mayo Clin. Proc., April 1, 2008; 83(4): 418 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Ballweg, G. Wernovsky, R. F. Ittenbach, J. Bernbaum, M. Gerdes, P. R. Gallagher, T. E. Dominguez, E. Zackai, R. R. Clancy, S. C. Nicolson, et al. Hyperglycemia After Infant Cardiac Surgery Does Not Adversely Impact Neurodevelopmental Outcome Ann. Thorac. Surg., December 1, 2007; 84(6): 2052 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ranasinghe, C. J. McCabe, D. W. Quinn, S. R. James, D. Pagano, J. A. Franklyn, and R. S. Bonser How Does Glucose Insulin Potassium Improve Hemodynamic Performance?: Evidence for Altered Expression of Beta-Adrenoreceptor and Calcium Handling Genes Circulation, July 4, 2006; 114(1_suppl): I-239 - I-244. [Abstract] [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, January 28, 2006; 332(7535): 246 - 246. [Full Text] [PDF] |
||||
![]() |
H. L. Lazar Hyperglycemia during cardiac surgery J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 11 - 13. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |